Business context and reporting period
iBio, Inc. (Nasdaq: IBIO) reported results of its October 14, 2026 annual meeting of stockholders. The company filed the report on October 19, 2026. The filing concerns corporate governance and capital authorization, not operating results.
Key financial and capital information
This 8-K does not report revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics. It provides no financial guidance or outlook.
- Stockholders approved an increase in authorized common shares from 275 million to 500 million. The amendment became effective upon filing with Delaware on October 16, 2026.
- Stockholders approved changes to the 2023 Omnibus Incentive Plan’s share-reserve increases: on January 1 of 2027–2029, the reserve increases by 5% of common shares outstanding plus 3% of shares issuable upon exercise of outstanding pre-funded warrants, based on December 31 balances. For 2030–2033, the annual increase is 5% of common shares outstanding; the Board may set a smaller increase before the applicable January 1.
Material changes and meeting results
- 48,244,264 shares were represented, constituting a quorum.
- The authorized-share increase passed with 45,730,093 votes for and 2,052,563 against. The plan amendment passed with 27,693,575 for and 8,263,100 against.
- William Clark and Gary Sender were elected as Class III directors for terms expiring at the 2029 annual meeting.
- Stockholders ratified Grassi & Co., CPAs, P.C. as independent auditor for the fiscal year ending June 30, 2027, and approved executive compensation on an advisory basis.
- The adjournment proposal passed, but no adjournment was needed because the authorized-share and plan proposals received sufficient votes.
Outlook, risks, and unusual items
The filing provides no business outlook, operating risks, or contingencies. The increased authorized share capacity and recurring incentive-plan share additions may enable future equity issuance and dilution; the filing does not state how many additional shares will ultimately be issued.
Investor verification points
- Review Exhibits 3.1 and 10.1 for the full text of the charter amendment and incentive-plan amendment.
- Verify the company’s outstanding shares, available plan reserve, and future share issuances in subsequent filings.
- Review subsequent filings for any Board decision to reduce a scheduled evergreen increase.